6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases

Help me get ahead. $200/year

Newsletters

Are the Digital Mental Health Treatment G Codes necessary? Or RTM dupes?

7.12.24

7 min. Read

Better Therapeutics shuts down. Mahana-Cara Care

3.18.24

5 min. Read

Virtual Clinics: Midi on payers. Bicycle providers may unionize.

3.15.24

5 min. Read

HCPCS and CPT decisions. Akili results. Click trials

3.08.24

7 min. Read

Details: Dario-Twill. Budweiser’s employee benefits.

2.28.24

8 min. Read

Virtual Clinics: Oshi’s self-pay pricing post Salvo’s pivot.

2.22.24

6 min. Read

De Novo: Samsung Galaxy Watch gets OTC sleep apnea detection

2.16.24

7 min. Read

Spring Health’s new biz. Coca-Cola’s benefits.

2.09.24

8 min. Read

Facebook’s RCT for AI bot Zenny. More trials

1.30.24

7 min. Read

Which virtual clinics got FTC-OCR letters?

1.19.24

6 min. Read

Scoop: Amwell in talks to buy Omada

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.